BRCA1 and ovarian cancer: For example, Chowdhury and colleagues have utilized a CRISPR‐Cas9 KO library to identify genes whose loss confers resistance to clinical PARP inhibition and to platinum‐based chemotherapy agents in BRCA1 null patient‐derived ovarian cancer cell lines [219].